{"groups":[{"description":"Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.","id":"FG000","title":"Small Bowel Adenocarcinoma"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Out of the 49 patients that was enrolled at MD Anderson Cancer Center Houston, Tx, only 20 patients had Small Bowel Adenocarcinoma. The rest had other solid tumors and their data was not used in the analysis for the group of patients with Small Bowel Adenocarcinoma."}